The United States market has been flat over the last week, but it has seen a significant rise of 34% over the past 12 months, with earnings forecasted to grow by 15% annually. In this context, ...
The firm will evaluate the engineered cell therapy in patients with melanoma, and non-small cell lung, head and neck, colorectal, pancreatic, and cervical cancer.
Sarcomatoid carcinomas of the stomach are rare and carry a poor prognosis. Surgical resection remains the primary treatment, though recurrence rates are high, and survival is limited. Further research ...